Speakers

Expand/Collapse

Claire Harris
VP Head of Biology
Gyroscope Therapeutics

Track B - Day 1 AM

12:30 pm | Supplementing Complement Factor I as a Therapeutic Strategy in Age-Related Macular Degeneration

Rosario Fernandez-Godino
Assistant Professor of Ophthalmology
Harvard Medical School; Drug Discovery & Disease Biology at Intergalactic Therapeutics

Christopher J. Campbell
Chief Scientific Officer
Aurin Biotech Inc.

Track A - Day 1 PM

3:00 pm | More Complement Crosstalk: The Ins and Outs of Sublytic MAC

Tim Higenbottam
Professor
Akari Therapeutics

Day Two

Thursday 13th December 2018

3:30 pm | Clinical Impacts of Controlling Dysregulation of the Terminal Complement Pathway and LTB4

Anita Hill
Vice President, Global Medical Affairs Lead Haematology & Nephrology, Consultant Clinical Development
Alexion

Day One

Thursday 13th December 2018

9:30 am | SWOT Analysis Panel Discussion Topics to be Addressed

Moshe Vardi
VP, R&D Global Medicine Team Leader Hematology/Nephrology
Alexion

Track B - Day 1 PM 2

4:00 pm | Validating Robust Combination Strategies Within the Context of the Patient Continuum of Care

Shamsah Kazani
Sr. Medical Director Hematology/Nephrology
Alexion

Day Two

Thursday 13th December 2018

2:30 pm | Complement Inhibition in the Setting of COVID-19

Sanjay Keswani
EVP & Chief Medical Officer
Annexon Biosciences

Day One

Thursday 13th December 2018

10:00 am | A Precision Medicine Approach to Classical Complement Mediated Diseases: Identifying the Right Patients to Achieve Better Outcomes

Lukas Scheibler
Chief Innovation Officer
Apellis

Track B - Day 1 AM

12:00 pm | To Be Announced

Inge Van de Walle
Principal Scientist
argenx

Day Two

Thursday 13th December 2018

12:30 pm | Upstream Complement Inhibition in Peripheral Auto- Immune Neuromuscular Neuropathies

Yingying Zhang
Postdoctoral Fellow
Boston Children’s Hospital (Michael Carroll’s lab)

Track A - Day 1 AM

12:30 pm | Spatial Transcriptomic Profiling of the Complement System in the Brain

Paul Morgan
Professor of Immunology
Cardiff University

Track A - Day 1 AM

11:30 am | Complement in Neurological Diseases: Roles in Pathology and Target for Therapy

Daniel Benjamin
Chief Executive Officer
Cascade Biotechnology Inc.

Day Two

Thursday 13th December 2018

12:00 pm | Cascade Biotechnology: Novel Therapeutic Opportunities Using Complement Depletion

Grant Blouse
Senior Vice President, Translational Research
Catalyst Biosciences

Day Two

Thursday 13th December 2018

11:30 am | Engineering Complement Factor I as a Protease Medicine: Replacement Therapy and Tuning Potency and Specificity for Complement-Mediated Disorders

Frank Baas
Chief Scientific Officer
Complement Pharma

Track B - Day 1 PM

3:00 pm | Terminal Pathway Inhibitors for Neurodegenerative Disorders

Sandra Wymann
Senior Manager, Translational Research
CSL Behring AG

Day Two

Thursday 13th December 2018

10:00 am | Recombinant Truncated Human CR1 as a Novel Complement Inhibitor

Renfeng Guo
Chief Scientific Officer
InflaRx N.V.

Jesse Hanson
Senior Scientist
Genentech, Inc

Track B - Day 1 PM

2:30 pm | Classical Pathway Activation in Neurodegenerative Disease

Edward F. Patz
Chief Executive Officer
Grid Therapeutics

Track A - Day 1 PM

2:30 pm | Complement Factor H as a Novel Drug Target for Cancer

Ruchi Sharma
Staff Scientist
National Eye Institute/NIH

Stephen Poor
Director External Opportunities & Translational Biomarkers
Novartis Institutes for Biomedical Research, Department of Ophthalmology

Track B - Day 1 AM

11:30 am | Roles of Systemic vs Local Complement Activation in Macular Degeneration

Shelia M. Violette
Co-Founder, Chief Scientific Officer & President of Research
Q32 Bio

Day Two

Thursday 13th December 2018

9:30 am | The Potential for Tissue Targeted Complement Inhibition: Generation of a Novel Therapeutic Platform

Michael Storek
Head of Complement Cluster
Sanofi

Day One

Thursday 13th December 2018

9:30 am | SWOT Analysis Panel Discussion Topics to be Addressed

9:20 am | Chair’s Opening Remarks

Curtis Rambaran
VP Head Clinical Science
Silence Therapeutics

Day Two

Thursday 13th December 2018

2:00 pm | siRNA Targeting Complement Protein 3 (C3) for Treatment of Patients with C3 Glomerulopathy (C3G)

Jeffry Lawrence
Interim Vice President, Clinical Development
Solid Biosciences

Day One

Thursday 13th December 2018

9:30 am | SWOT Analysis Panel Discussion Topics to be Addressed

Day Two

Thursday 13th December 2018

5:00 pm | Chair’s Closing Remarks

8:50 am | Chair’s Opening Remarks

Petra Duda
Head of Development – Zilucoplan
UCB

Track B - Day 1 PM

2:00 pm | Complement C5 Inhibition in Immune- Mediated Necrotizing Myopathy (IMNM)

Dorothy Schafer
Associate Professor of Neurobiology
UMass Medical School

Track A - Day 1 AM

12:00 pm | Complement-Mediated Synapse Loss: A Viable Therapeutic Target in Multiple Sclerosis

Hung D. Nguyen
Assistant Professor of Medicine
University of Central Florida College of Medicine

Track A - Day 1 PM

2:00 pm | Complement Targeting Therapies: A Promising Approach for the control of Graft-versus-host Disease and Tumor Relapse

Michael Holers
Professor of Medicine & Immunology
University of Colorado School of Medicine

Day Two

Thursday 13th December 2018

9:00 am | Next-Gen Complement Therapeutics: Opportunities for Indication Expansion and Tissue Targeted Immunomodulation

Dmitri Simberg
Associate Professor
University of Colorado

Track A - Day 1 PM 2

4:00 pm | Use of Complement Inhibitors to Block Opsonization and Immune Uptake of Nanoparticles